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Background: Infection is the leading cause of morbidity and the second leading cause of mortality in patients on
renal replacement therapy. The rates of bloodstream infection in hemodialysis patients vary according to the type
of venous access used. Gram-positive bacteria are most frequently isolated in blood cultures of hemodialysis
patients. This study evaluated risk factors for the development of bloodstream infections in patients undergoing
hemodialysis.
Methods: Risk factors associated with bloodstream infections in patients on hemodialysis were investigated using a
case–control study conducted between January 2010 and June 2013. Chronic renal disease patients on
hemodialysis who presented with positive blood cultures during the study were considered as cases. Controls were
hemodialysis patients from the same institution who did not present with positive blood cultures during the study
period. Data were collected from medical records. Logistic regression was used for statistical analysis.
Results: There were 162 patients included in the study (81 cases and 81 controls). Gram-positive bacteria were isolated
with the highest frequency (72%). In initial logistic regression analysis, variables were hypertension, peritoneal
dialysis with previous treatment, type and time of current venous access, type of previous venous access, previous
use of antimicrobials, and previous hospitalization related to bloodstream infections. Multiple regression analysis
showed that the patients who had a central venous catheter had an 11.2-fold (CI 95%: 5.17–24.29) increased chance of
developing bloodstream infections compared with patients who had an arteriovenous fistula for vascular access. Previous
hospitalization increased the chance of developing bloodstream infections 6.6-fold (CI 95%: 1.9–23.09).
Conclusions: Infection prevention measures for bloodstream infections related to central venous catheter use should be
intensified, as well as judicious use of this route for vascular access for hemodialysis. Reducing exposure to the hospital
environment through admission could contribute to a reduction in bloodstream infections in this population.
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Infection is the leading cause of morbidity and the sec-
ond leading cause of mortality among patients on renal
replacement therapy [1]. Mortality from all causes in pa-
tients on dialysis treatment is 6.5–7.9 times higher than
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unless otherwise stated.age, mortality from infection is two times higher than
that in a population of the same age with a diagnosis of
diabetes mellitus, neoplasms or congestive heart failure
[1]. According to the US Renal Data System [1], the
mortality rate at the end of the first year of hemodialysis
decreased by 38% for cardiovascular causes and by 50%
for infectious causes between 2000 and 2010. Among
patients on hemodialysis, the mortality rate decreased by
26% between 1985 and 2000 [1]. When comparing mor-
tality rates between the second and 12th month after ini-
tiation of hemodialysis, there was a significant reductionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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201 deaths per 1000 patients/year. The mortality rate from
infectious causes decreased from 43 to 19.4 deaths per
1000 patients/year [1].
North American data indicate that bloodstream infec-
tion (BSI) rates in patients on hemodialysis vary between
0.5 and 27.1 per 100 patients/month depending on the
type of venous access used [2]. More recent studies re-
port a reduction in the incidence of BSI in this popula-
tion between 1.09–0.89 and 2.04–0.75 per 100 patients/
month after implementation of specific control measures
[3,4]. This decrease was attributed to national initiatives
for the reduction of healthcare-related infections [5].
The literature reports that the use of a central venous
catheter (CVC), hypoalbuminemia, diabetes mellitus,
anemia, female gender and colonization by methicillin-
resistant Staphylococcus aureus (MRSA) are risk factors
for the development of BSI in hemodialysis patients [6-10].
Gram-positive bacteria are the most frequently isolated
agents in blood cultures from hemodialysis patients, mainly
S. aureus [7,10,11].
According to the US Renal Data System, the principal
morbidity event for hemodialysis patients is hospitalization
for infections, which showed an increase of 43% between
1993 and 2011. On the other hand, hospitalizations for
complications from venous access, showed a decrease of
57% [1].
Fram et al. reported that the risk factors for morbidity
and mortality among patients with BSI on hemodialysis
were age, isolation of S. aureus, and isolation of a resist-
ant microorganism [12].
Despite the best efforts to prevent BSI specific to
hemodialysis patients, BSI still has a large impact [13-16].
Therefore, the objective of this study was to evaluate risk
factors for the development of BSI in patients undergoing
a Brazilian hemodialysis center.
Methods
Ethical considerations
This study was conducted with the approval of the Com-
mittee on Ethics and Research at the Federal University
of São Paulo.
Design, period and location of the study
This was a retrospective, case–control study conducted
between January 2010 and June 2013 at the hemodialysis
satellite unit at the Kidney and Hypertension Hospital of
Foundation Oswaldo Ramos (HRIM/FOR) in the city of
São Paulo, Brazil. The HRIM/FOR is a nephrology ser-
vice, considered to be a national and international refer-
ence for teaching, research and care activities. It serves
an average of 400 patients in the dialysis program/month
(221 in hemodialysis). This institution follows rigorous
standards for medical record keeping.Patients with chronic renal insufficiency in a hemodialysis
program, ≥18 years of age, with BSI defined according
to the specific criteria of the National Healthcare Safety
Network Dialysis Event Surveillance Manual (Centers
for Disease Control and Prevention) [17], which defines
BSI as any positive blood culture, were considered for
enrollment in the study. We considered all positive blood
cultures regardless of the site where blood was drawn. For
common skin commensal pathogens (Staphylococcus co-
agulase negative including Staphylococcus epidermidis),
we considered BSI when pathogens were cultured from
two or more blood cultures and/or the patient was treated
by a physician [17,18]. Blood cultures were processed in
accordance with the recommendations of the Clinical and
Laboratory Standards Institute [19].
The cases were obtained from a survey of microbiology
laboratory records at the institution during the study
period. For patients who had more than one positive
blood culture, only the first episode was considered for
this study. These patients were included in the case group.
Hemodialysis patients at the same institution, ≥18 years of
age, and without positive blood cultures during the study
period were used as controls. Pairing criteria were: age,
time on hemodialysis, and diagnosis of diabetes mellitus.
The proportion of cases and controls was 1:1.
Study protocol and data collection
Data collection occurred through review of patients’
medical records. For the cases group, data collection in-
cluded sociodemographic characteristics, comorbidities,
body mass index [20], microorganisms in blood culture,
resistance profiles of antimicrobials, and previous treat-
ment for end stage renal disease. The type, location and
time of current and previous venous access, clinical
complications (transfusions, number of transfusions,
hospitalization because of infection, length of hospital
stay, prior antimicrobial use, previous hospitalization,
and number of previous hospitalizations), occurrence of
death, and transfer of treatment were recorded for a
period of 6 months prior to the BSI.
We defined short duration CVC as non-tunneled
hemodialysis CVC. However some patients remained
with this kind of catheter for a longer period due to
difficult inserting other more adequate vascular access
for hemodialysis. Long duration CVC was defined as
tunneled hemodialysis CVC [17]. The time of current
and previous venous accesses was stratified by period.
This was done as in some situations they may present
with similar periods.
Prior antimicrobial use was defined as every previous
antimicrobial treatment for at least seven days.
Death was considered to be related to BSI when it
occurred within 15 days after microbiologic diagnosis
of infection [21,22].
Table 1 Sociodemographic characteristics of the cases
group and control patients
Case (n = 81) Control (n = 81) p-value
Age 56 ± 17.1 53 ± 16.3 0.325
Sex
Male 36 (44.5) 47 (58.0) 0.083
Female 45 (55.5) 34 (42.0)
Race
White 49 (60.5) 55 (68.0) 0.325
Nonwhite 32 (39.5) 26 (32.0)
Educational level
No education 21 (26.0) 14 (17.0) 0.198
Elementary 28 (34.5) 22 (27.0)
High School 22 (27.0) 28 (35.0)
Higher education 10 (12.5) 17 (21.0)
Values are expressed as mean ± SD or n (%).
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record system, according to the previously mentioned
pairings, using the closest date of beginning dialysis in
relation to the case group. Of these, the same variables
described above were collected, except for the presence
of BSI at the beginning of the study.
A microorganism was considered multi-resistant when
it showed resistance to a pharmaceutical agent in three
or more classes of antimicrobials. Staphylococcus was
considered multi-resistant when it showed no suscepti-
bility to methicillin, and Enterococcus was considered
multi-resistant when it showed no susceptibility to
vancomycin (VRE) [23-25].
Statistical analysis
A descriptive analysis of the cases and controls was con-
ducted which examined the variables of interest. Data
are presented using absolute frequencies and percent-
ages for categorical variables, and mean ± standard devi-
ation for continuous variables. The primary outcome
was BSI. Associations between BSI and categorical vari-
ables were tested using the chi-square test, Fisher’s exact
test or likelihood ratio. The association between the con-
tinuous variables and the presence of BSI was examined
using the student’s t-test or Mann–Whitney test, as ap-
propriate. Univariate logistical regression was used to in-
vestigate the relationship between each independent
variable (preselected at the crossings where p ≤ 0.05) and
the dependent variable, BSI. To compare the outcomes
of patients that developed BSI and the patients that did
not developed BSI we used only the univariate logistical
regression.
Multiple logistic regression analysis was conducted to
determine the independent variables that continued to
be associated with BSI after inclusion in the model of
significant variables in univariate analysis. To include
the variables in the regression model, the forward step-
wise method was used. Odds ratios were calculated with
respective confidence intervals of 95%. SPSS version 19.0
(Chicago, IL, USA) was used for statistical analyses.
Results
The total number of patients in the dialysis program for
the study period was 353, of which 221 (62%) were on
hemodialysis and 132 (38%) were on peritoneal dialysis.
Ninety-three patients (42.1%) met inclusion criteria.
Twelve patients were excluded because they were unable
to be paired with a control. The final study population
included 162 patients (81 cases and 81 controls). For
nine cases, a control of the same age was not available,
and for three cases, a control with the same time on
hemodialysis was not available.
The sociodemographic characteristics of patients in-
cluded in the study are presented in Table 1. There wasno statistically significant difference in these characteris-
tics among the study population.
For clinical data related to dialysis treatment, the fol-
lowing variables were statistically significant (p ≤ 0.05) in
the initial analyses and were preselected for logistic re-
gression: associated diseases (hypertension), previous
treatment (history of peritoneal dialysis), current type of
venous access, duration of current venous access, use of
previous venous access, previous type and duration of
tunneled hemodialysis CVC, previous use of antimicro-
bials, and previous hospitalization. Duration of previous
venous access had a p-value of ≤0.05; however, it was
not included in regression analysis because of its low fre-
quency (Table 2).
Table 3 shows the results of logistic regression analysis.
In univariate analysis, variables significantly associated
with the occurrence of BSI were: hypertension, history of
peritoneal dialysis, type and duration of current venous
access, use of a tunneled hemodialysis CVC as previous
venous access, previous use of antimicrobials, and previ-
ous hospitalization (whether there had been a previous
hospitalization or not).
With multiple logistic regression analysis, current ac-
cess (CVC) and previous hospitalization were independ-
ent risk factors for the occurrence of BSI. Patients who
had a CVC showed an 11.2-fold (CI 95%: 5.17–24.29)
greater chance of developing BSI compared with patients
who had an AVF. Previous hospitalization increased the
chance of developing a BSI 6.6-fold (CI 95%: 1.9–23.09).
The most prevalent microorganisms isolated in blood
cultures taken from the case group were Gram-positive
bacteria (72.8%), followed by Gram-negative bacteria
(25.9%), and fungi (1.2%). Among the Gram-positive mi-
croorganisms, S. aureus was isolated in 32.1% of cases,
and of these, 38.5% showed resistance to methicillin.
Table 2 Clinical variables of interest of the case group and control patients
Case (n = 81) Control (n = 81) p-value
Comorbidities
Hypertension 71(87.6) 59 (72.8) 0.018
Cardiovascular diseases 17 (20.9) 12 (14.8) 0.306
Diabetes mellitus 26 (32.0) 26(32.0) 1.000
Others* 27 (33.3) 22 (27.2) 0.421
Body mass index, Kg/m2 24 ± 4.3 24 ± 3.9 0.945
Previous treatments 56 (69.1) 47 (58.0) 0.141
Type of previous treatments
Conservative 36 (64.3) 30 (37.0) 0.337
Peritoneal dialysis 19 (33.9) 9 (11.1) 0.038
Hemodialysis 17 (30.4) 9 (11.1) 0.087
Transplant 15 (26.8) 8 (9,9) 0.115
Duration of hemodialysis treatment, months 29 ± 39.2 36 ± 42.1 0.276
Type of current venous access
AVF** 25 (30.9) 64 (79.0) <0.001
Tunneled hemodialysis CVC*** 52 (64.2) 13 (16.0)
Non-tunneled hemodialysis CVC 4 (4.9) 1 (1.2)
PTFE Graft**** 0 (-) 3 (3.7)
Location of current venous access
Upper arm 24 (29.6) 67 (82.7)
Jugular vein 50 (61.7) 13 (16.0)
Subclavian vein 7 (8.6) 0 (-)
Femoral vein 0 (-) 1 (1.2)
Duration of current venous access
0–30 17 (21,0) 3 (3.7) <0.001
30–180 days 27 (33.3) 8 (9.9)
>180 days 37 (45.7) 70 (86.4)
Previous venous access (6 months) 26 (32.1) 11 (13.6) 0.005
Number of previous accesses 1.2 ± 0.41 1.3 ± 0.46 0.744
Type of previous venous access
AVF 7 (8.6) 3 (3.7) 0.192
Tunneled hemodialysis CVC 14 (17.3) 5 (6.2) 0.028
Non-tunneled hemodialysis CVC 5 (6.2) 6 (7.4) 0.755
PTEF Graft 5 (6.2) 1 (1.2) 0.210
Location of tunneled hemodialysis CVC
Jugular vein 13 (16.0) 3 (3.7)
Subclavian vein 0 (-) 1 (1.2)
Location of non-tunneled hemodialysis CVC
Jugular vein 4 (4.9) 6 (7.4)
Subclavian vein 1 (1.2) 0
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Table 2 Clinical variables of interest of the case group and control patients (Continued)
Duration of previous venous access
AVF
0–30 0 1 (1.2)
30–180 days 4 (4.9) 0 (-)
>180 days 3 (3.7) 2 (2.5)
Tunneled hemodialysis CVC
0–30 4 (4.9) 0 (-) 0.034
30–180 days 6 (7.4) 5 (6.2)
>180 days 4 (4.9) 0 (-)
Non-tunneled hemodialysis CVC
0–30 1 (1.2) 6 (7.4)
30–180 days 3 (3.7) 0
>180 days 1 (1.2) 0
PTFE Graft**
0–30 0 (-) 0 (-)
30–180 days 1 (1.2) 0 (-)
>180 days 4 (4.9) 1 (1.2)
Transfusions 11 (13.6) 7 (8.6) 0.317
Number of transfusions 1.9 ± 2.7 1 (-) 0.246
Hospitalizations due to infection 21 (25.9)
Length of hospital stay 16.9 ± 16.4
Previous use of antimicrobials 28 (34.6) 14 (17.3) 0.012
Previous hospitalizations 19 (23.5) 4 (4.9) <0.001
Number of previous hospitalizations 1.5 ± 1.2 1(-) 0.259
Values are expressed as mean ± SD or n (%). *hypothyroidism, hyperthyroidism, neoplasm and systemic lupus erythematosus; **AVF: arteriovenous fistula;
***CVC: central venous catheter; ****PTFE, polytetrafluoroethylene.
Table 3 Univariate and multivariate logistic regression analyses
Simple logistic regression Multiple logistic regression
OR (IC 95%) p-value OR (IC 95%) p-value
Diagnosis of hypertension 2.65 (1.16–6.03) 0.021
Previous treatment (peritoneal dialysis) 2.45 (1.03–5.81) 0.042
Type of current venous access
CVC* vs. AVF** 10.72 (5.09–22.57) <0.001 11.2 (5.17–24.29) <0.001
Duration of current venous access
0–30 vs. > 180 days 10.72 (2.95–38.96) <0.001
30–180 days vs. > 180 days 6.39 (2.64–15.45) <0.001
Use of previous venous access 3.01 (1.37–6.62) 0.006
Tunneled CVC (previous access) 3.18 (1.09–9.28) 0.035
Prior antimicrobial use 2.53 (1.21–5.28) 0.013
Previous hospitalizations 5.90 (1.91–18.24) 0.002 6.63 (1.9–23.09) 0.003
*CVC: central venous catheter; **AVF: arteriovenous fistula.
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Table 5 Progression of the patients, cause of death and






Progression of the patients
Death 15 (18.5) 0 (-) <0.001
Transfer of care 9 (11.1) 5 (6.2) 0.263
Duration of treatment 41 (50.6) 70 (86.4) <0.001
Peritoneal dialysis 9 (11.1) 1 (1.2) 0.009
Transplant 7 (8.6) 5 (6.2) 0.549
Cause of death in the cases
BSI 7 (46.7)
Cardiovascular diseases 2 (13.3)
Other* 6 (40.0)
Total 15
Time of death post-BSI
4.6 ± 5.5
Values are expressed as mean ± SD or n (%). *neoplasms, infections at other
sites, cardiovascular diseases, and noninfectious complications in the
vascular access.
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S. epidermidis (13.6%), with 100% resistance to methicil-
lin. Of the Gram-negative microorganisms isolated,
13.6% were of the enterobacteriaceae family and 12.3%
were non-fermenters. For Gram-negative microorgan-
isms, 33.3% were multi-resistant (Table 4).
MRSA was isolated in 10 patients. Two of these pa-
tients had previous exposure to vancomycin and had a
minimum inhibitory concentration to vancomycin of
≤0.05 μg/mL and 1.0 μg/mL.
With regard to progression for cases and controls,
there were no significant differences in variables. Death
occurred only in the cases group, retention in treatment
was higher in controls, and shift to peritoneal dialysis
showed a higher frequency in the cases group. Fifteen
patients (46.7%) died from BSI, two (13.3%) from cardio-
vascular disease, and six (40%) from other causes, such
as neoplasms, infections at other sites, and noninfectious
complications at the vascular access. The median time
to death after BSI was 4.6 ± 5.5 days (Table 5). Among
the patients that died due to other causes, the death oc-
curred from 45 to 672 days after the BSI.
Discussion
For patients undergoing renal replacement therapy, in-
fection is the leading cause of morbidity and the second
leading cause of mortality [1]. In Brazil, it is estimated
that 97,586 patients currently receive chronic dialysis
treatment [26]. According to North American data, theTable 4 Microorganisms isolated in the cases group, and
profiles of resistance
MR S Total
Gram-positives 28 (47.5) 31 (52.5) 59 (72.8)
Staphylococcus aureus 10 (38.5) 16 (61.5) 26 (32.1)
Staphylococcus epidermidis 11 (100.0) 0 (-) 11 (13.6)
Staphylococcus coagulase
negative non S. epidermidis
4 (57.1) 3 (42.9) 7 (8.6)
Enterococcus faecalis 1 (33.3) 2 (66.7) 3 (3.7)
Other Gram-positives* 3 (33.3) 9 (66.7) 12 (14.8)
Gram-negatives 7 (33.3) 14 (66.7) 21 (25.9)
Enterobacteriaceae** 4 (36.4) 7 (63.6) 11 (13.6)
Non-fermenters*** 3 (30.0) 7 (70.0) 10 (12.3)
Fungi 0 (-) 1 (100.0) 1 (1.2)
Candida albicans 0 (-) 1 (100.0) 1 (1.2)
Total of microorganisms 81
Values are expressed as mean ± SD or n (%). MR: multi-resistant. S: sensitive.
*Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus,
Streptococcus bovis, Streptococcus pyogenes, Staphylococcus simulans,
Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus
lugdunensis; **Enterobacteriaceae: Enterobacter spp, Enterobacter aerogenes,
Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Serratia marcescens,
Proteus mirabilis; ***Non-fermenters: Acinetobacter baumannii, Pseudomonas
aeruginosa, Stenotrophomonas maltophilia.rates of BSI among hemodialysis patients range between
0.5 and 27.1 per 100 patients/month depending on the
type of venous access used [2]. Results of a Brazilian
study reported that rates varied between 0.55 and 7.32
per 1000 venous accesses/day [27].
In the present study, risk factors for BSI were evalu-
ated in patients on hemodialysis at a hemodialysis ser-
vice in São Paulo, Brazil. The study was a case–control
design, which can analyze risk factors related to a deter-
mined condition. Patients presenting with BSI during
the study period were included as cases, and controls
were those patients who did not develop the studied
event (pairing criteria: age, previous time on hemodialysis,
and diagnosis of diabetes mellitus).
Use of a CVC compared with use of an AVF, and previ-
ous hospitalization were independent risk factors for the
occurrence of BSI among patients on hemodialysis treat-
ment. Use of a CVC was associated with an increased risk
of developing BSI (OR: 11.2; CI 95%: 5.17–24.29; p < 0.001)
compared with the use of an AVF. This finding aligns with
previous trials of antimicrobial locks, which reported a
higher occurrence of BSI among hemodialysis patients with
CVC (3-4 cases per 1000 catheter-days) [28]. In a longitu-
dinal cohort study, Xui et al. found that the rates of BSI in
patients using CVC were three times higher than in pa-
tients using AVF (p < 0.001) [8]. A case–control study
conducted at a university hospital in Greece demon-
strated, through multivariate logistic regression, that pa-
tients using CVC had a higher risk of BSI compared with
patients using AVF (OR: 2.93; p = 0.047) [10].
In the current study, only five patients (four cases and
one control) used a non-tunneled hemodialysis CVC. In
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days and were awaiting the manufacture of an AVF, and
the other two had been undergoing treatment for a lon-
ger period of time and had spent longer with a non-
tunneled hemodialysis CVC because of difficulties in the
insertion of a tunneled hemodialysis CVC or the manu-
facture of an AVF.
Previous hospitalization increased the risk of BSI 5.33-
fold (p = 0.003). There are few reports in the literature
on the association between BSI and previous hospitaliza-
tions in patients undergoing hemodialysis treatment.
Nguyen et al. in a study performed between 2005 and
2011, evaluated BSI from MRSA in patients on dialysis
treatment, and found that 70% of patients who developed
BSI were hospitalized at least once in the year prior to the
infection [6]. In a study by Barbosa et al. the researchers
reported that, in 320 chronic renal patients, previous
hospitalization was an important risk factor for colonization
of multi-resistant microorganisms (e.g., VRE) [29]. And
Aktas et al. in a study of 70 patients on dialysis treatment,
reported a higher colonization for MRSA in patients who
had been hospitalized within the previous 6 months com-
pared with those who had not [30].
In univariate logistic regression analysis, systemic ar-
terial hypertension, peritoneal dialysis as a prior treat-
ment, duration of venous access, presence of previous
venous access, use of tunneled hemodialysis CVC as a
previous access, and previous antimicrobials were associ-
ated with a higher occurrence of BSI. No data was found
in the literature on the possible relationship between
systemic arterial hypertension and previous peritoneal
dialysis with the occurrence of BSI in this population.
For examination of time of duration of current venous
access as a risk factor, BSI was found to be associated
with access that had been gained within 30 days. Dur-
ation of current venous access was analyzed using three
categories (0–30 days, 30–180 days, and >180 days). BSI
was higher in those who had had the CVC inserted
within 30 days, which underscores the need for greater
care during the CVC insertion procedure. Napalkov et
al. in a study that evaluated infectious and noninfectious
complications in CVC, reported that the majority of BSI
occurred within the first 90 days, with an incidence rate/
1000 catheter-days of 5.1 (CI 95%: 3.7–4.3) [31]. There
was also a higher risk of infection for catheters inserted
within the 6 months following infection, reinforcing the
need for care during this period.
The use of previous venous access and, primarily, pre-
vious access of tunneled hemodialysis CVC, was associ-
ated with a higher occurrence of BSI. As mentioned
above, studies have reported that CVC use is associated
with a higher incidence of BSI compared with the use of
an AVF [8-10]. References to previous venous access as
a risk factor for BSI were not found in the literature.Previous use of antimicrobials was associated with a
higher occurrence of BSI (OR: 2.53; p = 0.013). As with
other variables, data were collected on the use of antimi-
crobials within 6 months before the event. We found no
specific studies that related prior antimicrobial exposure
to BSI in patients undergoing hemodialysis treatment.
However, Lim et al. in a case–control study conducted
with patients seen in the emergency department of a ter-
tiary hospital in Australia, showed through multivariate
analysis that prior antimicrobial use increased the risk of
developing BSI by multi-resistant microorganisms (OR:
5.49; p < 0.001) [32]. According to the Centers for Disease
Control and Prevention, the rational use of antimicrobials
is an important measure for controlling the spread of
multi-resistant microorganisms [23].
Gram-positive microorganisms were the most prevalent
(72.8%) found in the current study. Among them, S. aur-
eus was the most frequently isolated (32.1%), with about
38.5% resistant to oxacillin. Other studies have also re-
ported a high prevalence of Gram-positive microorganisms
in patients undergoing hemodialysis treatment, primarily
S. aureus [7,10,11]. Despite the high prevalence of Gram-
positive microorganisms observed in the current study,
Gram-negative microorganisms accounted for 25.9% of
isolates in blood cultures. In a university hospital in Spain,
microorganisms isolated in blood cultures from patients
with kidney disease were: Gram-negative bacteria, 52.3%;
Gram-positive bacteria, 46.5%; and fungi, 1.2%. Escherichia
coli was the most frequent microorganism (27%) [33].
With regard to resistance profiles, microorganisms
such as MRSA and VRE have been isolated in surveil-
lance cultures collected from patients on dialysis treat-
ment [29,34,35]. Aktas et al. used molecular typing to
show a high similarity between MRSA strains isolated
from surveillance cultures and clinical cultures collected
from patients on dialysis treatment [30]. And a study
conducted at long-term care facilities in Hong Kong re-
ported a significant dissemination of MRSA, reinforcing
the need to adopt measures to reduce the transmission
of this microorganism [36].
The independent risk factors for BSI identified in the
current study were use of a CVC compared with use of
an AVF, and previous hospitalization. Although previous
studies have indicated a relationship between the presence
of CVC and BSI, our study expands the characteristics of
this group, highlighting the importance of care during the
initial period and the period of up to 6 months of catheter
duration. Furthermore, the study highlights the import-
ance of previous hospitalization as a risk factor for BSI.
To the best of the authors’ knowledge, this factor has
not been reported in previous studies and requires fur-
ther research.
This study had some limitations inherent in the retro-
spective character of the data collection. However, patient
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nificant caution, given the characteristics of a service dedi-
cated to the treatment of chronic renal patients, and
followed the high standards of the organization. Addition-
ally, as there are standardized protocols for performing
blood cultures for these patients, it is unlikely that events
were underdiagnosed in the study period.
Preventative measures against BSI related to CVC should
be strengthened and effectively applied to hemodialysis
treatment units, as well as reducing the use of this device
whenever possible, prioritizing the use of AVF. Considering
that previous hospitalization was an independent risk factor
for BSI, patients who developed BSI after hospitalization
are probably infected by microorganisms during this
period. Standard precautions should be enforced to pre-
vent microorganism dissemination during hospitalization.
A reduction in the number of infections in this popula-
tion may contribute to a decrease in hospital admissions,
since infections are a leading cause of hospitalization in
patients on hemodialysis treatment.Conclusions
The risk factors for BSI in chronic renal disease patients
receiving hemodialysis were previous hospitalization and
use of a CVC. The most prevalent microorganisms
were Gram-positive bacteria, of which 47.5% were
multi-resistant. The results of this study suggest the
need to intensify measures to prevent and control BSI
in hemodialysis patients, among which are specific
measures for insertion and maintenance of the CVC,
and the judicious use of this device. Efforts should be
made to reduce exposure of these patients to hospitalization
to minimize the risk of BSI. Future research could evaluate
the impact of surveillance cultures to prevent microorganism
dissemination in this population.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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